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Subcellular fractionationLinear poly(amidoamine)s (PAAs) have been designed to exhibit minimal non-specific toxicity, display pH-
dependent membrane lysis and deliver genes and toxins in vitro. The aim of this study was to measure PAA
cellular uptake using ISA1-OG (and as a reference ISA23-OG) in B16F10 cells in vitro and, by subcellular
fractionation, quantitate intracellular trafficking of 125I-labelled ISA1-tyr in liver cells after intravenous (i.v.)
administration to rats. The effect of time after administration (0.5–3 h) and ISA1 dose (0.04–100 mg/kg) on
trafficking, and vesicle permeabilisation (N-acetyl-b-D-glucosaminidase (NAG) release from an isolated
vesicular fraction) were also studied. ISA1-OG displayed ~60-fold greater B16F10 cell uptake than ISA23-OG.
Passage of ISA1 along the liver cell endocytic pathway caused a transient decrease in vesicle buoyant density
(also visible by TEM). Increasing ISA1 dose from 10 mg/kg to 100 mg/kg increased both radioactivity and
NAG levels in the cytosolic fraction (5–10 fold) at 1 h. Moreover, internalised ISA1 provoked NAG release
from an isolated vesicular fraction in a dose-dependent manner. These results provide direct evidence, for
the first time, of PAA permeabilisation of endocytic vesicular membranes in vivo, and they have important
implications for potential efficacy/toxicity of such polymeric vectors.ed at Tel.: +44 02083318207;
k (S.C.W. Richardson),
ll rights reserved.© 2009 Elsevier B.V. All rights reserved.1. Introduction
The majority of gene therapy clinical trials currently use viral
vectors, and effective cytosolic delivery of all therapeutically impor-
tant macromolecular drugs (e.g. small interfering ribonucleic acids
(siRNAs), DNA, proteins, peptides) is still the major challenge
restricting their clinical development. Even viral vectors have major
limitations [1]. They can be immunogenic [2,3], may produce
insertional mutagenesis (causing cancers such as leukaemia) [1],
and their pharmacokinetics can be non-target specific. Although an
attractive alternative, and despite more than 20 years of research and
development, lack of clinically measurable success using polymeric
non-viral vectors has diminished credibility of this approach. Such
synthetic vectors often show poor transfection efficiency coupled
with transient gene expression [3,4]. They can display an unfavour-
able pharmacokinetic profile with high levels of liver/lung capture
[5,6] and many have unacceptably toxicity [4,7,8]. Moreover most
polyplexes are ultimately impractical to manufacture on an industrial
scale and/or use clinically. Many of these problems are due to either
the cationic charge of the polymers used [9] and/or lack of
homogeneity of the products prepared. Acknowledged as a keybiological rate-limiting step for the development of effective
biocompatible, polymer-based cytosolic delivery systems is still
poorly efficient endosomal escape which precludes adequate and
reproducible intracellular delivery (cytosolic or nuclear) of a
therapeutic dose [10–12]. Rather than simply screening for in vitro
therapeutic activity using libraries of novel vectors, there is a clear
need for rational design based upon a fundamental understanding of
material physico-chemical properties.
During the development of linear poly(amidoamine)s (PAAs) as
pH-responsive endosomolytic polymers (Fig. 1) we identified specific
structures and salt form (ISA23·HCl and ISA1·HCl) that showed
considerable promise [13–16]. These PAAs (ISA1 IC50 for B16was 3.1±
0.7 mg/mL, ISA23 IC50 for B16was>5 mg/mL [13]) have relatively low
toxicity compared to other polycationic vectors (>100 fold less toxic
than poly(ethyleneimine) (PEI (Mw 70,000 g/mol)) and poly-L-lysine
(PLL Mw 72,000 g/mol)), and the ability (ISA23·HCl) to escape
reticuloendothelial system (RES) clearance after intravenous (i.v.)
administration allowing tumour targeting by the enhanced perme-
ability and retention (EPR) effect [13]. Although cytosolic delivery of
genes by ISA23·HCl [15], and the delivery of non-permeant protein
toxins such as gelonin and ricin A chain by ISA1·HCl [16] has been
demonstrated in vitro, titration studies which systematically varied
PAA:toxin ratio showed that delivery efficiency was likely to be
impractical for repeated clinical dosing.
Therefore, to guide the development of more effective PAA
chemistries better able to promote rapid (within <10 min), transient,
Fig. 1. Poly(amidoamine)s structures. ISA1 (1); ISA1-tyr (2); ISA23 (3); ISA1-OG (4);
ISA23-OG (5).
Fig. 2. Markers used and scheme showing methodology used for subcellular
fractionation studies. Panel (a) simplified cartoon of the mammalian endocytic system
andmarkers used in this study (modified from [33]). Panel (b) protocol used to perform
differential centrifugation with inset TEMs of fractions obtained.











Yand more efficient endosomal escape at pH 6.5 (Fig. 2a), we began to
systematically define the physico-chemical properties of ISA23 and
ISA1 (Fig. 1; Table 1). PAA shape, size, and pH-responsive changes in
conformation were determined using small angle neutron scattering
(SANS) [17,18], and the rate of diffusion in solution was defined using
pulsed-gradient spin-echo NMR [17]. Most recently PAA interaction
with model micelles [19], and model membranes whose composition
was chosen to mimic the plasma, endosomal and lysosomal
membrane was measured using surface tension and electron plasmon
resonance techniques in combination with SANS [19].
The aims of these studies were to define the endocytic uptake
and intracellular trafficking of ISA1. First B16F10 cells (previously
used to study PAA-mediated toxin delivery [16]), and ISA1-Oregon
Green (OG) and ISA23-OG together with flow cytometry were used
to quantitate uptake in vitro, and fluorescence microscopy was also
used to visualise PAA and gelonin-Texas Red (TR) vesicular loca-
lisation over time. Subsequently liver subcellular fractionation was
used to track the intracellular fate of ISA1 after intravenous (i.v.) to
rats. Whereas the amphoteric 125I-labelled ISA23-tyr evades liver
capture (<10% dose in the liver at 1 h) after i.v. injection, the more
cationic 125I-labelled ISA1-tyr displays substantial liver localisation
(>80% dose, 1 h) [13] thus providing a useful probe for these studies.
Both time- and dose-dependent trafficking of ISA1 was quantified
and the fractions obtained were also visualised by transmission
electron microscopy (TEM). Cytosolic radioactivity levels were used
to quantitate 125I-labelled ISA1-tyr endosomal escape and cytosolic
N-acetyl-b-D-glucosaminidase (NAG) release provided an indicator
of PAA-induced vesicle permeabilisation. Following i.v. administra-
tion of increasing doses of ISA1, the ISA1-containing endosomal/
lysosome vesicles were isolated from rat liver and the in vitro
release of NAG was measured over time. For comparison, the iso-lated vesicle fraction was also incubated with ISA1 added to the
culture medium (i.e. the outside). These experiments also allowed
comparison with vesicle permeabilisation mediated by PEI and (N-
[1-(2,3-dioleoyloxy)propyl]-N,N,N,trimethylammonium methylsul-
fate) DOTAP [20,21].2. Materials and methods
2.1. Materials
Polymers: ISA1, ISA1-tyr, ISA23 [13] and ISA1-NH2 and ISA23-NH2 (containing a terminal amine group) [22] were synthesised as previously
described. The ISA1-tyr derivative was radio-iodinated and the PAA-NH2 derivatives bound to OG as described below. The chemical
characteristics of all PAAs used in these studies are given (Fig. 1 and Table 1). PEI (Mn 70,000 g/Mol) was from Sigma-Aldrich (Pool, UK).
General materials: These materials were from Sigma-Aldrich (Pool, UK) unless stated otherwise. PBS tablets were from Oxoid (Hampshire,
UK), liquid nitrogen, carbon dioxide and oxygen were from BOC (Surrey, UK). PD10 columns and sodium [125I]iodide were from GE Healthcare
(Chalfont St. Giles, UK). Dialysis membranes (14,000 g/mol cut-off), were from Millipore (Dundee, UK).
Table 1
Characteristics of the PAAs and probes.
Probe Mwa (g/mol) Specific activity of OG/TR (µg/mg conjugate) or labelling efficiency (%) Free marker (% total)
ISA1-OG 22,700 1.5 <5b
ISA23-OG 16,700 2.2 <5b
ISA23 16,500 NA NA
125I-labelled ISA1-tyr 15,000 61.6 1.2% free [125I]iodide
Gelonin-TR 29,000 75 <5b
NA, not applicable.
a By gel permeation chromatography.
b Not detectable by TLC and or PD10 column chromatography.











YIn vitro assays: Anti-EEA1 monoclonal antibodies were from BD Bioscience (Oxford, UK), Vectorshield was from Vector Laboratories
(Peterborough, UK), pioloform coated grids were from Agar Scientific (Essex, UK). Donkey anti-mouse conjugated Alexafluor 594, Texas Red
(TR)-succinimide ester and Oregon Green (OG)-succinimide ester, RPMI medium, 4′,6-diamidino-2-phenylindole (DAPI) foetal calf serum (FCS)
and glutamate were from Invitrogen (Paisley, UK). B16F10 cells were from Prof. Ian Hart (St Thomas' Hospital, UK) [13].
In vivo experiments: Wistar rats were from Banton & Kingman (Hull, UK) and isoflurane was from Abbott labs (Kent UK) and animal
experiments carried out in accordance with UK Home Office Guidelines for Animal Experimentation.
2.2. Methods
2.2.1. Synthesis and characterisation of PAA-OG probes (ISA1-OG and ISA23-OG) and 125I-labelled ISA1-tyr:
ISA1-NH2 or ISA23-NH2 was dissolved (separately) in 5 mL sodium bicarbonate buffer 0.1 M pH 8. The OG-succinimide ester (0.5 mg) was
dissolved in 50 mL of DMSO and added to the polymer solution and left stirring at room temperature for 2 h. Separation of ISA1-OG and ISA23-OG
from the reaction products was achieved using PD10 columns followed by TLC analysis (usingmethanol) of the fractions to ascertain the purity of
the conjugates prepared. For microscopy and polymer uptake analysis 1 mg/mL ISA1-OG and ISA23-OG and, where stated, the non-toxic
concentration of 10 µg/mL gelonin was used [16].
Synthesis of Gelonin-TR: TR-succinimide ester (0.5 mg) was dissolved in DMSO (50 µL). Gelonin (1 mg) was dissolved in sodium bicarbonate
buffer 0.1 M pH 8 and stirred gently. The TR-succinimide ester was then added and the reaction was left for 2 h at room temperature in the dark.
Separation of gelonin-TR from the reaction products was achieved using PD10 columns. The determination of free label in the purified product
was conducted as before using TLC.
125I-labelled ISA1-tyr was prepared using sodium [125I]iodide and chloramine T as previously described [13]. Free sodium [125I]iodide was
removed by exhaustive dialysis against sodium chloride 0.9% w/v and paper electrophoresis was used to assess labelling efficiency, specific
activity and product purity.
2.2.2. Fluorescence microscopy to visualise the uptake of ISA1-OG, ISA23-OG and gelonin-TR by B16F10 cells
B16F10 cells in RPMImedium supplementwith 10% v/v FCS and glutamate (5 mM)were seeded in 6 wells plate (1×106 cells/well) containing a
sterile cover slip. After 24 h cells theywere incubated with gelonin-TR, ISA1-OG, or ISA23-OG for the times and at the concentrations indicated. Cells
were visualised directly in fresh complete media containing DAPI (300 nM) and red lysotracker dye (10 nM dissolved in DMSO) where indicated.
2.2.3. Immunofluorescence microscopy
B16F10 cellswere prepared as above. After 24 h themediumwas replaced by freshmedium containing ISA1-OGor ISA23-OG (10 mg/mL) and the
cells were incubated at 37 °C for 10 min. Cover slips bearing adherent cellswere thenwashedwith PBS (3×5 minwashes at room temperature), and
the cellswerefixed in freshparaformaldehyde (2%w/v (in PBS)) for 20 min at room temperature. Thefixed cellswere thenwashed three times in PBS
(5 min each at room temperature), and then permeabilised and quenched using PBS containing Triton X-100 (0.02% v/v) with glycine (50 mM). The
cells were first incubated for 60 min at room temperature with primary anti-EEA1 monoclonal antibody (diluted 1:1000 in PBS containing bovine
serum albumin (1% v/v) and, after three washes in PBS, with the secondary antibody donkey–anti-mouse conjugated Alexafluor 594 also diluted
1:1000 inPBS containingbovine serumalbumin 1%v/v) for 60 min at room temperature. After 3 additional 5 minwashes in PBS at roomtemperature,
the cover slips were mounted using Vectashield (Vector Laboratories) containing DAPI (300 nM) and imaged using an SP5 scanning confocal
microscope (Leika; Wetzlar, Germany).
2.2.4. Flow cytometry
B16F10 cells in RPMI medium supplemented with FCS (10% v/v) and glutamate (5 mM) were seeded in 12 well plates (1×105 cells/well). After
24 h, themediumwas replacedwith 1 mL of fresh, completemedia containing either ISA1-OG or ISA23-OG (10 µg/mL) and the cells were incubated
at 37 °C or 4 °C (these cells were pre-incubated at 4 °C for 30 min before adding the PAA solution) for the times indicated. At each time point the cells
were rinsed 3 times with ice-cold PBS, harvested by scraping with a sterile rubber policeman and analysed by flow cytometry. Untreated cells were
used as a reference control and in each case 10,000 events were acquired. All experiments were carried out 4 times and the results expressed as:
cell‐associatedfluorescence =
percentagepositivecells × mean fluorescence
100
:
2.2.5. Determination of the intracellular trafficking of 125I-labelled ISA1 in rat liver cells-effect of time and dose
Male Wistar rats (~250 g) were anaesthetised with isoflurane (2% v/v) and O2 (4% v/v). A mixture of 125I-labelled-ISA1-tyr (5×105cpm in
sterile saline) and non-radiolabelled ISA1 added to give the dose required (0.04 mg/kg to 100 mg/kg) was then injected into the caudal vein of
the tail [13]. Rats were killed at various time points (30–180 min), the liver removed, rinsed in pre-chilled (4 °C) sucrose (250 mM) and blotted











Ydry before weighing. The liver was then cut into 3–5 mm3 cubes with scissors (on ice), forced through a wire mesh (1 mm3) and the crude
homogenate was re-suspended in a 2.5 mL ice-cold fractionation buffer (sucrose 250 mM containing EDTA1 mM) per g of liver. This crude
homogenate was further homogenised using a Potter-Elvehjem homogeniser (0.019 cm clearance; 5×10 s up and down strokes at 3000 rpm)
(ThermoFisher Scientific, Hampshire, UK) and the resultant homogenate was weighed and a 1 mL sample was removed and frozen in liquid
nitrogen for use during subsequent analyses. This fraction was denoted the total homogenate fraction (H fraction).
2.2.6. Subcellular fractionation of rat liver
The protocol used for fractionation of isolated liver cells is summarised in Fig. 2b. Unless otherwise stated all centrifugation steps were
performed at 4 °C. The total H fraction was centrifuged at 750 ×g for 2 min and the pellet (intact cells) was re-suspended in ice-cold sucrose
(250 mM; 2 mL), weighed, 1 mL removed and frozen (WC fraction). The decanted supernatant was also weighed, and 1 mL was removed and
snap frozen.
The remaining supernatant was then centrifuged at 2000 ×g for 2 min and the resulting pellet was re-suspended in 5 mL of ice-cold
fractionation buffer before re-centrifugation at 2000 ×g for 2 min to wash the pellet. The final pellet was re-suspended in 2 mL of fractionation
buffer, weighed and a 1 mL aliquot was frozen. This was denoted the nuclear fraction (N fraction). The resulting supernatants from the first
2000 ×g centrifuge step and the wash (also at 2000 ×g step) were pooled and centrifuged at 6750 ×g for 4 min. The supernatant and the pellet
were again separated and the pellet was washed. The supernatants obtained were combined, and the final pellet was re-suspended in 5 mL of
fractionation buffer, weighed, and a 1 mL aliquot was frozen. This fraction was denoted the heavy mitochondrial fraction (HM fraction).
The combined supernatants were centrifuged at 22,000 ×g for 9 min. As above, the pellet waswashed and the final pellet was re-suspended in
5 mL of fractionation buffer and weighed before a 1 mL aliquot was removed and snap frozen. This was denoted the light mitochondrial fraction
(LM fraction). Finally the combined supernatants from this step were centrifuged at 48,000 ×g for 70 min, to obtain a pellet which was re-
suspended in 2 mL of fractionation buffer and denoted the microsomal fraction (MC fraction). The final supernatant represented the cytosolic/
soluble fraction (C fraction). Again, both fractions were weighed and aliquots were snap frozen in liquid nitrogen. All fractions were kept at
−20 °C until assayed for biochemical markers as described below and, where appropriate for radioactivity using a RioGamma 1240 counter (LKB-
Wallac; Victoria, Australia). Where % values pertaining to radioactivity recovery occur in the text, reference is made to % total counts per min
(cpm) recovered.
2.2.7. Characterisation of subcellular fractions
Where necessary fractions were diluted with PBS to ensure assays could be related to the linear range of the respective calibration curve.
Protein assay: BCA reagent (200 mL of a mixture of CuSO4 pentahydride 4% w/v and bicinchoninic acid at a ratio of 1:50) was added to fraction
samples (10 mL; in triplicate) and was incubated at room temperature for 30 min. Bovine serum albumin (BSA) standards (~2–50 µg/mL) were
used to calibrate this assay. Results were expressed as protein (mg/mL) in each fraction and also related, as a percentage, to the total recovered
protein from all the fractions.
N-acetyl-b-D-glucosaminidase assay: NAGwasmeasured using an assay adapted from [23]. 50 µL of each fraction, 250 µL sodium-citrate buffer
(0.2 M pH 5.0, containing Triton X-100 0.1% (v/v)) and the sample were warmed to 37 °C. Then the substrate 4-methylumbelliferyl-N-
acetamido-β-D-glucosaminide (100 µL; 10 mM) in sucrose (0.25 M) was added and the mixture was incubated at 37 °C for 1 min. Sodium
bicarbonate (3 mL; 1 M) was added to stop the reaction, and activity was assessed fluorometrically (emission at 450 nm and excitation 365 nm).
Transmission electronmicroscopy (TEM) of isolated fractions: The LM fractionwas prepared from rat liver after i.v. injection of saline (control) or
ISA1 treatment (25 mg/kg) as described above. Samples were fixed for 45 min at 4 °C using a 1:2 v/v solution of glutaraldehyde (2.5% w/v) and
osmium tetroxide (1% w/v). The fixed fractions were briefly washed in sodium cacodylate buffer (0.2 M; pH 7.2), before rinsing in distilled water
for 45 min. Theywere stainedwith uranyl acetate (0.5%w/v) for 30 min, before dehydration (3×10 minwashes) in a graded series of 50–100% v/v
acetone solutions. Finally, the samples were embedded in araldite resin and incubated at 37 °C overnight. Thin sections were cut and placed onto
pioloform coated grids and they were counterstained with 0.5% w/v uranyl acetate and 0.5% w/v lead citrate for 10 min. Samples were visualised
using 201 and 208 TEM microscopes (Philips, Eindhoven, The Netherlands).
2.2.8. Measurement of NAG release from isolated rat liver vesicles incubated with ISA1 outside or containing ISA1 inside
To investigate the effect of ISA1 on vesicle membrane permeability when added outside, a LM fraction was first prepared from rat liver as
described above. The vesicles were resuspended in sucrose–EDTA containing HCl (0.1 M) and a 2 mL sample was incubated with ISA 1, (0.5 mL;
concentration 0–2 mg/mL) in saline (0.9% w/v) or saline containing Triton X-100 (0.2% w/v) at 37 °C (Fig. 8c). At various times aliquots (50 µL)
were removed and assayed for NAG activity as described above. The results were expressed as a percentage lysis compared to the Triton X-100
control.
In parallel experiments the effect of ISA1 internalised into liver endocytic vesicles on membrane integrity was investigated. First, ISA1 (doses
from 0 to 50 mg/kg in sterile saline) was injected i.v. into the tail vein of anaesthetised rats. After 30 min the animals were killed, the liver was
taken, and subcellular fractionation was undertaken as described above to obtain the LM fraction. This vesicular fraction was then re-suspended
in 1 mL ice-cold fractionation buffer. As above, aliquots (50 µL) were removed at various times, and assayed for NAG activity as described above.
2.2.9. Data presentation
The distribution of NAG and radioactivity in the fractions was expressed as a percentage of the total recovered in all fractions. A vesicle
stability index (VSI) was also calculated using the following formula:
Percentage NAG or radioactivity intheHMfraction + PercentageNAG or radioactivity intextLMfraction
Percentage NAG orradioactivity in theCfraction
The higher the VSI, the greater vesicular stability.
Statistical significance was calculated using the Student's t-test for small sample sizes with the aid of Prism QuickCalcsTM software from
Graphpad Inc. (San Diego, CA).
Fig. 3. Typical PD10 chromatography profiles for ISA23-OG and gelonin-TR showing
purity of probes used for fluorescence microscopy (Fig. 4).












3.1. Uptake and intracellular trafficking of PAA-OG conjugates in B16F10
cells in vitro
The ISA1-OG, ISA23-OG conjugates and gelonin-TR used contained
only a minimal amount of free fluorophore (Table 1; Fig. 3).
Fluorescence microscopy revealed little gelonin-TR uptake by
B16F10 cells after 5 h (Fig. 4a panels i and ii) and a similar picture
was seen at 24 h (data not shown). However, when added in
combination with ISA1-OG, gelonin-TR uptake was dramatically
increased (Fig. 4a panels iii–iv), and in many cases the vesicles seen
displayed a red ‘halo’ consistent with gelonin-TR release into the
cytosol. The inset (Fig. 4a panel v) shows a typical magnified profile.
Lysotracker, labelling of acidic endo-lysosomes revealed some degree
of co-localisation with ISA1-OG and this was most evident in small
puncta located within the cell cortex (Fig. 4a panels vi–viii). Although
ISA23-OG also showed co-localisation with lysotracker (Fig. 4a panels
ix–xi), unlike ISA1, this PAA did not enhance gelonin-TR uptake.
Indeed, the pattern of cellular fluorescence observed when incubated
with the combination was similar to that seen in cells incubated with
toxin alone (Fig. 4a panels ix–xi). Cells incubated with ISA1-OG for
10 min and subsequently probed with an antibody (labelled red) to
EEA-1 (Fig. 4b panel i) showed EEA-1 co-localisation of ISA1-OG
(Fig. 4b panel ii and arrows depicting co-localisation in individual
vesicles are shown in Fig. 4b panel iii).
Comparison of the uptake of ISA1-OG and ISA23-OG by B16F10
cells using flow cytometry indicated that both PAAs displayed a
similar degree of non-specific binding at 4 °C (Fig. 5). However,
whereas increasing incubation temperature to 37 °C led to a marked
increase in cell association/uptake of ISA1-OG this was not seen for
ISA23-OG. Indeed the uptake of ISA1-OG was ~60 times greater.
3.2. Subcellular fate of 125I-labelled ISA1-tyr in liver cells after i.v.
injection
The liver fractionation procedure used was reproducible in terms of
both the protein and NAG distribution and the range of RSA of protein
and NAG obtained for each fraction are shown in Table 2. The total
recovery achieved for protein was ~100% and for NAG was ~80%. TEM
confirmed the anticipatedmorphology of the fractions prepared (Fig. 2).
Importantly, the 125I-labelled ISA1-tyr probe used contained a minimal
amount of free [125I]iodide (1.2% (total cpm)) (Fig. 6a; Table 1).
In the first experiment, 1 h after injection of a tracer dose
(0.04 mg/kg) of 125I-labelled ISA1-tyr most radioactivity and NAG
(Fig. 6b) were detected in the HM fraction (72–73%). When non-
radiolabelled ISA1 was added to this tracer to increase the dose
administered to 10 and 100 mg/kg respectively, it was shown that as
the dose increased the distributions of both recovered radioactivity
and NAG changed markedly. The radioactivity recovered in the HM
fraction at 60 min fell from 73.1% to 42.8% at 10 mg/kg and then to
40.8% at 100 mg/kg. Concomitantly, there was a small increase in
radioactivity detected in the LM fraction. Most importantly, there was
also a significant increase in the radioactivity recovered in the C
fraction; rising from 2% at 0.04 mg/kg to 19.5% (10 mg/kg) and 16.2%
(100 mg/kg) (Fig. 6c).
The NAG distribution also changed significantly. At the lowest
dose 72.3% of the NAG activity in the HM fraction was documented
(Fig. 6d). Increasing ISA1 dose to 10 mg/kg caused a fall in NAGFig. 4. Fluorescence microscopy of B16F10 cells incubated with ISA1-OG, ISA23-OG, and gel
Vertical line 1—gelonin-TR (i) and a merged DAPI and TR-gelonin image (ii). Line 2—an ISA
merged image incorporating a DAPI counter-stain (v). The higher magnification inset (v) sho
white circle highlights ISA1-OG containing vesicles not indicating an acidic pH (viii). Line 4
prior to fixation. The red channel shows anti-mouse secondary antibody-TR hybridised to an
localisation is indicated by arrows in (iii). The size bar represents 5 µm.recovery in the HM fraction to 25.8% accompanied by a significant
redistribution into the LM fraction where NAG levels rose to 55.7%
from a baseline of 19.4%. As seen for the radioactivity redistribution,
this transfer of NAG between HM and LM fractions was accompanied
by a statistically significant increase in NAG, from 2.5% at low dose to
10.4% at 10 mg/kg, in the C fraction (Fig. 6d). Interestingly, when ISA1
dose was increased to 100 mg/kg, the NAG distribution in the HM
(79.5%) and LM (5.8%) fractions reverted to a pattern similar to that
seen at the lowest dose. However, it was noteworthy that cytosolic
levels remained higher at ~10.3% (Fig. 6d). The effect of ISA1 dose on
the cytosolic transfer of radioactivity and NAG can be clearly seen
when the data are expressed as a VSI (Fig. 6e).
When the liver fractionation was conducted at various times after
the i.v. administration of ISA1 (10 mg/kg) the distribution of both
radioactivity and NAG changed over time (Fig. 7). At 30 min
radioactivity (Fig. 7a) and NAG (Fig. 7b) were primarily associated
with the HM fraction. However by 60 min distribution of both
markers shifted from the HM into the LM fraction. The NAG
redistribution was most striking with the LM level of 3.7% at 30 min
rising to a level of 55.7% at 60 min. Interestingly by 120 min there was
a return of NAG distribution to predominantly the HM fraction with
levels in the LM fraction falling to 12.0% where it remained (12.4%) at
180 min (Fig. 7a). Between 30 min and 60 min NAG cytosolic levels
increased from 3.9% to 10.4%. These C fraction NAG levels remained at
~10% over the rest of the time course (Fig. 7a).
Although the recovered radioactivity in the HM fraction remained
highest throughout the time course, radioactivity detected in the LMonin-TR or their mixtures. Probes were used at the concentrations indicated. Panel (a)
1-OG and gelonin-TR mixture viewed with the FITC filter (iii), the TR filter (iv) and a
ws putative gelonin-TR vesicle escape (arrow). Line 3—ISA1-OG and lysotracker red; the
—an ISA23-OG and gelonin-TR mixture. Panel (b) ISA1-OG was internalised for 10 min
EEA1-specific primary monoclonal antibody (i) and the green channel, ISA1-OG (ii). Co-












Fig. 5. Uptake of PAA-OG by B16F10 cells in vitro assessed by flow cytometry. Panel (a)
ISA1-OG and (b) ISA23-OG. Cells were incubated at the temperatures shown and
“uptake” estimated by subtracting values obtained at 4 °C. Data represent mean±S.D.
(n=3).
Table 2














Whole cell (WC) 651 39 35 36 0.7–0.9
Nuclear (N) 114 7 3 3 0.4–0.7
Heavy mitochondrial (HM) 167 10 17 18 1.8–2.8
Light mitochondrial (LM) 61 4 21 22 5.5
Microsomal (M) 544 33 13 13 0.4–0.5
Cytosolic (C) 126 8 8 8 1.0–1.4
Liver homogenate (H) 1670.44 122.61
Recovery (% w/w) 100 79
a RSA; The relative specific activity calculated by dividing the percentage distribution
of NAGase by the fractional percentage distribution of protein in each fraction.











Yfraction did also increase; from 7.0% at 30 min to 21.0% at 60 min. As
for NAG, these LM radioactivity levels fell again at 120 and 180 min; in
this case to 11%. Cytosolic radioactivity was 5.3% at 30 min and
although it did rise to 19.5% at 60 min levels detected at 120 and
180 min fell back to 6.2% and 4.1% respectively. Again the VSI
underlined cytosolic entry (Fig. 7c) with the lower index indicating
increased membrane permeability.
TEM indicated that the vesicles isolated from rat liver after i.v.
injection of ISA1 were markedly different in appearance being larger
and swollen compared to the more electron-dense vesicles isolated
from rats injected with saline (Fig. 7a,b). These observations were
consistent with the increased buoyant density of the vesicles
containing NAG and radioactivity at 60 min after injection of ISA1.
3.3. ISA1 permeabilisation of vesicles in vitro and ex vivo
Isolated liver cell vesicles were incubated in a medium designed to
minimise osmotic breakage in vitro even the controls showed 15–20%
free NAG at the start of the experiment. This was unlikely caused by
the buffer as previous research has shown that a lysosome-rich
fraction from rat liver normally exhibits latency with respect to
enzyme activity in the range of 10–20% of the total activity in that
fraction for several hours after its isolation. Addition of increasing
concentrations of ISA1 to the incubationmixture caused no significant
increase in NAG release after 45 min or 2 h (Fig. 8c) (ISA 23 also
showed no significant NAG release in this assay; results not shown).
In contrast, addition of PEI did induce pH-dependent release of NAG
(Fig. 8d) indicating vesicle membrane destabilisation.
When ISA1-containing vesicles were isolated from liver after prior
i.v. injection of the PAA NAG release over time was however observed.The extent of release was dose-dependent (Fig. 8d). For example,
10 mg/kg ISA1 did not significantly elevate NAG release relative to the
control, but release was a 3-fold higher (2 h) after administration of
an ISA1 dose of 50 mg/kg. These observations were compatible with
the ISA1-induced increase in cytosolic NAG seen in the earlier
subcellular fractionation studies (Figs. 6 and 7).
4. Discussion
Previous PAA-mediated cytotoxicity assays showed that ISA1
could deliver the non-permeant protein toxins gelonin and ricin A
chain into the cytosol resulting in cytotoxicity [16]. In contrast ISA23
could not. Evaluation of a library of PAAs having different monomer
composition led us to suggest [24], as others have done for other
polymers [25,26], that PAA endosomolytic activity was not simply
attributable to proton sponge effect. We postulate that intracellular
vesicle permeabilisation involves physical PAA–membrane interac-
tion. Consistent with this hypothesis are previously reported studies
in the red blood cell (RBC) haemolysis model, which showed that
PAAs added to RBCs cause pH-dependent haemoglobin release
depending on their chemical composition and salt form [13,14,24].
In an attempt to better understand mechanistically the reasons for
the differences in ISA1- and ISA23-mediated toxin delivery first
experiments defined the cell uptake of both using OG-labelled PAAs.
Flow cytometry showed that ISA1-OG uptake was much more rapid
(~60 fold) than seen for ISA23-OG (Fig. 5a). This would presumably
lead to a much higher intravesicle concentrations of ISA1 and the
temperature-dependency of cell association was indicative of an
active process. (It is noteworthy that previous studies with OG-
labelled polymers have shown both stability of the conjugate (little or
no OG release over a 2 h incubation) and minimal pH- or
concentration-dependent OG fluorescence quenching [27].) Endocytic
internalisation of ISA1-OG by B16F10 cells in vitro was confirmed
visually by fluorescence microscopy (Fig. 4). The higher uptake of
ISA1-OG compared to ISA23 is not surprising as, at neutral pH, this
cationic PAA will interact with anionic plasma membrane compo-
nents and thus display adsorptive rather than solely fluid-phase
endocytosis. In comparison at neutral pH ISA23 carries a net negative
charge. The low levels of cell interaction observed at 4 °C and indeed
minimal internalisation at 37 °C (Fig. 5) suggest little membrane
Fig. 6. Effect of i.v. dose on intracellular fate of ISA1. Panel (a) characterisation of 125I-labelled ISA1-tyr reaction mixture and purified conjugate by paper electrophoresis. Peak I is the
125I-labelled ISA1-tyr and peak II is free [125I]iodide. Purified and non-purified polymer are shown. Panel (b) distribution of radioactivity andNAG in liver cells (n=3) after injection of
125I-labelled ISA1-tyr (0.04 mg/kg). The effects of increasing the dose on panel (c) radioactivity and panel (d) NAG distribution are shown. Data are also expressed as a VSI in panel—
the lower the ratio the greater the vesicle permeability (e). P-values denote the statistical difference compared to the 0.04 mg/kg dose. Data represent mean±S.D. (n=3).











Yinteraction. Previously reported SANS studies showed that ISA23 coil
expansion resulting from polymer backbone protonation only
occurred at pH 5 and below, pH values not normally associated with
the endosomal compartment [18].
Although potentially interesting, further dissection of the endo-
cytic pathways utilised by these PAAs in vitro was not undertaken as
such studies are likely to be irrelevant to increased understanding
intracellular fate in vivo. The endocytic process is complex, and both
trafficking pathways and vesicle pH are cell type-dependent [28] so
general conclusions regarding entry mechanisms and intracellular
fate of lipoplexes and polyplexes are impossible to make [29].
Moreover, many use a combination of fluorescent-labelled vectors
and/or payload with chemical inhibitors (reviewed in [30]) to gain
clues as to trafficking pathways knowing that these studies areadditionally complicated by the fact that many inhibitors are not
uniquely pathway-specific. Such compounds exert non-specific
toxicities themselves so data require careful interpretation [30].
Roles for glycosaminoglycans, cell polarization and cell cycle have
been proposed but all do vary from one cell type to another [28].
Nevertheless it has been suggested, and seems likely, that intracellular
trafficking, rather than degree of uptake or cytotoxicity, may be the
most important factor for cytosolic delivery [31].
Although fluorescence microscopy gives only a qualitative per-
spective, here it was clear that co-incubation of ISA1 with gelonin-TR
resulted in much greater cell uptake of gelonin-TR. Furthermore,
many vesicle profiles along the edge of the B16F10 cells displayed a
red halo at the vesicle margin (denoted by an arrow in Fig. 4a panel v)
suggesting gelonin-TR release into the cytosol facilitated by PAA-
Fig. 7. Effect of time after administration on the cell subcellular fate of 125I-labelled ISA1-tyr at 10 mg/kg. Panel (a) shows the NAG distribution, panel (b) radioactivity distribution,
and panel (c) VSI. Data represent mean±S.D. (n=3).











Ymediated permeabilisation. Interestingly, these vesicle profiles were
very similar to those seen during studies on the intracellular fate of
PEI-ribozyme complexes where the release from vesicles visualised
using video scanning laser confocal microscopy was described as a
“sudden event, very likely due to bursting of these organelles” [32].
The co-localisation of ISA1-OGwith the early endosomal marker EEA1
(Fig. 4b), and our previous studies have shown that B16F10
internalised markers localise to an EEA1 positive and transferrin
receptor positive early endosomes after ~5–10 min [33] suggest that
gelonin-TR release seen in Fig. 4a occurs from an early endosomal
compartment.
When intracellular trafficking of ISA1 in liver cells was quantified
using the 125I-labelled ISA1-tyr probe, endocytic internalisation of
PAA in vivo was confirmed for the first time. Interestingly, although
both were principally recovered in the HM and LM fractions, the
distribution of ISA1 (radioactivity) and NAG showed both time- and
dose-dependent changes in their intracellular distribution. Two very
important features emerged.
First was the transfer of radioactivity and NAG into the cytosolic
fraction over time indicating vesicle permeabilisation. These effects
were ISA1 dose-dependent. There was 2-fold more radioactivity
(~20%) in the cytosolic fraction at 60 min than NAG (~10%) (Fig. 6)
but this level did not increase with time which might be suggestive
either of transient permeabilisation and/or that radiolabelled-ISA1
interacts with and remains associated with the interior face of the
lysosomal membrane. The NAG release observed (~10% the total
enzyme activity) has important implications for the design and use of
a PAA-based cytosolic delivery system. In a positive sense this
observation verifies that ISA1 can disrupt the lysosomal membrane
sufficiently to enable a protein of molecular weight 71,000 g/mol to
escape. Albeit that 90% of NAG remained associated with the organelle
fractions, release could be a concern in the context of potential acute/chronic toxicity. Few authors acknowledge that non-viral vectors
designed to permeabilise intracellular vesicle membranes can be
inherently harmful if they induce either catastrophic intracellular
vesicle rupture (acute toxicity) or low level, but sustained, perturba-
tion of the normal physiological functioning of the endosomal/
lysosomal apparatus. Prolonged leakage of lysosomal enzymes
would endanger cell viability and may cause other undesirable
patho-physiological changes.
The second, and an important observation arising from these
subcellular fractionation studies, was the redistribution of the
lysosomal marker NAG and radioactivity from the HM to LM fractions
over the first 60 min with a subsequent return to the baseline
distribution after 180 min (Figs. 6 and 7). Internalisation of ISA1
delayed trafficking leading to transient accumulation of vesicles with
increased buoyant density (profiles seen also by TEM; Fig 8a,b). This is
likely due to inhibition of entry into the late endosome–lysosome
hybrid organelle [34] where enzymatic digestion occurs [35]. It is
possible that ISA1membrane interaction inhibits vesicle fusion, and/or
causes an efflux of hydrogen ions resulting in an increased vesicular
luminal pH and halting the continued destabilisation of themembrane
by ionized (and now de-protonating) PAAs. Interestingly fluorescence
microscopy showed ISA1-OG also within vesicles that appeared to be
in non-acidic i.e. none-lysotracker positive (Fig. 4 panel vii).
Alternatively, buffering of the late endosome pH by ISA1would inhibit
vesicle–vesicle fusion which is thought to be dependent upon vesicular
pH regulated by the V-ATPase [36,37] or lysosomal reformation [34].
These observations were consistent with those of Wattiaux and
colleagues who showed, using liver subcellular fractionation, that [35S]
plasmid-containing lipoplexes [38] and poly-lysine polyplexes [39]
exhibited a delay (>5 h in the case of lipoplexes) in trafficking to
lysosomes (arylsulfatase positive vesicles) compared to control
probes present there at 1 h. Their poly-L-lysine-containing polyplexes
Fig. 8.Morphology and stability of LM vesicular fraction in the presence of ISA1 (outside or inside). Panels (a) and (b) show TEM pictures of the LM fraction either isolated from rat
liver as a control, or isolated from liver obtained after i.v. administration of ISA1 respectively. Panel (c) shows the effect of ISA1 concentration on NAG release when the polymer was
added to isolated LM vesicles, and panel (d)NAG release induced by PEI (0.5 mg/mL) added to isolated LM vesicles for 30 min at the pHs shown. In both cases results are expressed as
a percentage of the triton X-100 control (100% release). Panel (e) shows the NAG release from the LM vesicles isolated from liver taken 30 min after i.v. administration of ISA1 at
doses shown. Data represent mean±S.D. (nh=3).











Ytrafficked faster than poly-D-lysine polyplexes, even though both
were endocytosed at the same rate and it was suggested that the
digestion of the vector in a pre-lysosomal compartment is required to
allow endocytosed plasmid DNA to rapidly reach lysosomes [39].
Whatever the mechanism(s) the time dependency suggests that the
biological effects of ISA1 are transient, but it is clear that they are also
dose-dependent.
Therewas a lack of electron densitywithin the swollenmembrane-
delimited structures containing ISA1 (Fig. 8b) and as the outer
membranes can be seen it is possible that ISA1 is interacting with
the inner leaflet causing pore formation driven by the protonation of
the PAAs backbone. The studies on lysosomal latency clearly
demonstrated that, unlike PEI which shows pH-dependent lysosomal
membrane permeabilisation when added to the outside of a vesicular
fraction, ISA1 needs to interact with the luminal as opposed to the
cytosolicmembrane leaflet to promoteNAG release (Fig. 8c and d) and
that permeabilisation is dose-dependent. The fact that PEI and DOTAP
[21] cause significant release of lysosomal enzymeswhen added to the
outside of isolated vesicles, although less pronounced at pH 7.4, is
indicative of the potential to design PAAs that will display more
selective, and specific endosomal escape mechanism. Tuning the
physico-chemical properties of PAAs to increase the speed ofmembrane permeabilisation whilst minimising lysosomal enzyme
escape and perturbation of the endocytic pathway should give vectors
with an optimal safety/efficacy profile in vivo.
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